Source 1
This report ends in .gov, indicating it as a highly reliable source. Updated in May 2010, authors Jeremy Greene and David Herzberg discuss the recent emergence of direct-to-consumer pharmaceutical marketing, noting the conditions that allowed this practice. Greene works with the Department of the History of Science at Harvard University, while Herzberg works with the Department of History at the University of Buffalo. Both have high credibility. Herzberg and Greene are both proponents for more aggressive response to misleading information in direct-to-consumer advertisements. They include graphics showcasing the progression to more overt pharmaceutical advertising in their report. While there are no links within the document itself, there are many contained in the end notes of the report.
Source 2
This source is a .org site, showing that it is a non-profit organization site. It was last updated in December 2013, a somewhat recent update. I chose this site because I noted opponents saying that PhRMA, the organization which wrote his article, was a proponent of direct-to-consumer advertising. PhRMA, short for the Pharmaceutical Research and Manufacturers of America, declares themselves as "the country’s leading biopharmaceutical researchers and biotechnology companies." PhRMA describes DTCA as a method of disseminating public information, rather selling product. PhRMA touches on the benefits of DCTA, such as encouraging discussion between patients and doctors. No graphics exist on the page. The short article contains many hyperlinks to other parts of PhRMA's site.
No comments:
Post a Comment